Regulatory Submission in Europe in Absence of Reference product [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2021-03-23 09:51 (512 d 06:55 ago) – Posting: # 22290
Views: 6,535

Hi Abhay Patil!
In absence of Innovator product in EU and UK market for FDC, you may have to do BE against individual drug substance innovator product. Please see Guideline on clinical development of fixed combination medicinal products.
Regards,
Dshah

Complete thread:

UA Flag
Activity
 Admin contact
22,305 posts in 4,668 threads, 1,587 registered users;
online 7 (1 registered, 6 guests [including 3 identified bots]).
Forum time: Wednesday 17:46 CEST (Europe/Vienna)

There is no point in being precise when you don’t know
what you’re talking about.    attributed to John Tukey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5